UNSPSC 51121922: Meribendan

This classification denotes a cardiotonic agent with the molecular formula C15H14N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4WYD7I9GF4, chemically known as 4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2h)-pyridazinone but generally known as meribendan, which bears US NIH Compound Identifier 5464106. European Medicines Agency schedules Meribendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08776MIG.

UNSPSC 51121922 Meribendan, a Commodity code, addresses pharmaceutical supply for state and local emergency medical services, public health agencies, and multi-state cooperative purchasing programs. The code encompasses the acquisition of emergency medications and generic pharmaceuticals for use by fire rescue departments, health agencies, and networked government facilities. State and local issuing bodies soliciting under this code include municipal fire and rescue services (such as Tampa Fire Rescue), state health and human services departments, and multi-state cooperative purchasing alliances that serve participating state and local jurisdictions. The scope of work involves sealed-bid procurement of specific medication line items with firm pricing, managed expiration dates, warranty coverage, and delivery timelines measured in days to weeks; vendors must meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, maintain Safety Data Sheets, and in some cases secure relationships with authorized pharmaceutical wholesalers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 (due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year term with renewal options; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling preliminary market research for a future formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendor certification of cGMP compliance and DSCSA compliance with mandatory relationships with at least two of three authorized wholesalers and pricing evaluated 75 percent on competitiveness.